Trevena Inc (OQ:TRVN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 955 Chesterbrook Blvd Ste 110
Tel: N/A
IR: See website
Key People
Leon O. Moulder
Independent Chairman of the Board
Carrie L. Bourdow
President, Chief Executive Officer, Director
Barry Shin
Chief Financial Officer
John M. Limongelli
Chief Administrative Officer, Senior Vice President, General Counsel, Secretary
Scott Applebaum
Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs
Mark A Demitrack
Senior Vice President and Chief Medical Officer
Yacoub Habib
Senior Vice President - Business Development and Corporate Planning
Robert T. Yoder
Senior Vice President and Chief Business Officer
Business Overview
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Financial Overview
For the nine months ended 30 September 2019, Trevena Inc revenues decreased from $5.5M to $0K. Net loss decreased 19% to $18.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General & Administrative Exp decrease of 36% to $7.9M (expense), Research and development - Balancing val decrease of 19% to $9.8M (expense).
Employees: 29 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $31.49M as of Sep 30, 2019
Annual revenue (TTM): $0.23M as of Sep 30, 2019
EBITDA (TTM): -$26.01M as of Sep 30, 2019
Net annual income (TTM): -$26.40M as of Sep 30, 2019
Free cash flow (TTM): -$22.35M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 92,593,239 as of Nov 1, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization